Negative gene sets in the cancer-immunity cycle—including PD-1, PD-L1, LAG-3, TIM-3, and TIGIT—can have an inhibitory function that primarily acts to modulate active immune responses in the tumor bed (step 7) (Chen and Mellman 2013; Chen and Mellman 2017). This evidence concerns the gene PDCD1 and cancer.